FCGR3A and neoplasm: In the mouse model of tumors overexpressed with EGFR A431, compared to the control groups of each antibody, treatment with free α-EGFR and α-CD16/α-4-1BB NPs or α-EGFR NPs, and α-CD16/α-4-1BB NPs led to moderate delays in tumor growth (P=0.0046 and 0.0061 versus the nontreatment group).